Triodos Investment Management BV increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 19.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,000 shares of the medical equipment provider's stock after buying an additional 6,750 shares during the quarter. Triodos Investment Management BV's holdings in Hologic were worth $3,028,000 at the end of the most recent reporting period.
A number of other hedge funds also recently modified their holdings of HOLX. General Partner Inc. bought a new position in shares of Hologic in the 4th quarter valued at $26,000. Groupama Asset Managment grew its position in Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after acquiring an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC raised its stake in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after acquiring an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 159 shares in the last quarter. Institutional investors own 94.73% of the company's stock.
Hologic Stock Performance
Shares of Hologic stock traded down $0.18 during trading hours on Tuesday, hitting $61.59. 514,566 shares of the company's stock traded hands, compared to its average volume of 2,422,959. The company has a fifty day simple moving average of $65.08 and a 200-day simple moving average of $73.11. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The stock has a market capitalization of $13.82 billion, a price-to-earnings ratio of 19.43, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 12-month low of $60.33 and a 12-month high of $84.67.
Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.
Analysts Set New Price Targets
Several equities analysts recently commented on the stock. Royal Bank of Canada dropped their price objective on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research note on Thursday, February 6th. Wolfe Research began coverage on Hologic in a research note on Friday, December 13th. They issued a "peer perform" rating for the company. BNP Paribas upgraded Hologic to a "strong-buy" rating in a research report on Tuesday, December 10th. Citigroup dropped their price target on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Finally, Evercore ISI decreased their target price on Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research note on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $84.62.
Get Our Latest Stock Report on Hologic
Hologic Profile
(
Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
See Also
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
